Samidorphan/Olanzapine

萨米多芬/奥氮平

Report date: 2025/05/21 20:00:31

Base Information

Drug NameSamidorphan/Olanzapine
Drug Alias NameALKS 33/olanzapine奥氮平/SamidorphanOlanzapine/ALKS 33Samidorphan/OlanzapineOlanzapine and Samidorphan +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D1 receptor antagonistsDopamine D2 receptor antagonistsSerotonin 2 (5-HT2) receptor antagonists +[4] 
TargetsDopamine D1 receptorDopamine D2 receptorSerotonin 2 (5-HT2) receptor +[4] 
Therapy Area/IndicationsBipolar I DisorderSchizophreniaPsychotic Disorders +[6] 
Global Approved IndicationsSchizophreniaBipolar Disorder
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/05/28
Country/TerritoryBulgariaUnited StatesUkraine +[20] 
CombinationsYes SamidorphanOlanzapine
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesAlkermes PlcAlkermes IncQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsBipolar I DisorderSchizophreniaPsychotic Disorders +[5] 
Inactive IndicationsAlcoholism

Other Information

ATC CodeN05AH03
Related LinksN/A